For dietary support in the management of
early memory loss and dementia

Neurothrive targets certain metabolic processes and abnormalities identified with early memory loss and common to many sufferers of dementia; with a particular emphasis on individuals diagnosed with, or at risk of hyperhomocysteinemia, Alzheimer's dementia or vascular dementia. This product also acts as a Trimonoamine Modulator (TMM).

Neurothrive has been developed through academic collaboration with a number of high-profile researchers, including researchers from Oxford University, United Kingdom. This product has been developed under an exclusive relationship with Merck KGaA, Darmstadt, Germany.

This project is supported by the Australian Government Department of Industry, Innovation and Science through a commercialisation grant as part of the Entrepreneurs’ Programme.

Neurothrive is expected to be available in Australia in late 2018.